When pregnancy is detected, AZOR should be discontinued as soon as possible. See WARNINGS AND PRECAUTIONS, Fetal/Neonatal Morbidity and Mortality.
In volume- and/or salt-depleted patients, symptomatic hypotension due particularly to the olmesartan component may occur after initiation of treatment with AZOR. Treatment should start under close medical supervision.
Patients, particularly those with severe obstructive coronary artery disease, may develop increased frequency, duration, or severity of angina or acute myocardial infarction on starting calcium channel blocker therapy.
In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. There has been no long-term use of olmesartan medoxomil in patients with unilateral or bilateral renal artery stenosis, but similar effects would be expected with AZOR because of the olmesartan medoxomil component.
Since amlodipine is extensively metabolized by the liver and the plasma elimination half-life (t1/2) is 56 hours in patients with severely impaired hepatic function, caution should be exercised when administering AZOR to patients with severe hepatic impairment.
The only adverse event that occurred in greater than 3% of patients treated with AZOR and more frequently than placebo was edema (22.2% vs 12.3%).
Please see full prescribing information for AZOR.
WelChol (colesevelam HCI) is indicated for LDL-C lowering and was
approved by the U.S. Food and Drug Administration (FDA) for marketing in
May 2000. WelChol is the top-selling branded drug in the bile acid
sequestrants (BAS) class. WelChol is different from most other
cholesterol-lowering drugs on the market because it is non-systemic,
meaning that the bod
|SOURCE Daiichi Sankyo, Inc.|
Copyright©2007 PR Newswire.
All rights reserved